Clinical bottom line
Circulating tumor DNA (ctDNA) analysis shows promise as a biomarker for guiding treatment adaptation in metastatic castration-resistant prostate cancer (mCRPC). Early changes in ctDNA levels during therapy may provide prognostic information beyond prostate-specific antigen (PSA) kinetics, potentially enabling more timely and personalized treatment decisions. However, clinical integration remains investigational, pending further validation in prospective studies.
What the evidence shows
Recent studies have demonstrated that ctDNA profiling can detect tumor-specific genomic alterations and quantify tumor burden in mCRPC patients. Herberts et al. (2020) identified biallelic DNA repair defects in ctDNA from prostate cancer patients, highlighting the potential of ctDNA to reveal actionable genomic alterations relevant for targeted therapies.
Lisek et al. (2026) showed that early on-treatment ctDNA kinetics provide additional prognostic value beyond PSA changes in mCRPC patients receiving systemic therapy. Their findings suggest that a molecular response detected by ctDNA reduction correlates with improved clinical outcomes, supporting ctDNA as a dynamic biomarker for treatment monitoring.
Tolmeijer et al. (2024) further corroborated the utility of early ctDNA measurements as a response assessment tool in mCRPC, demonstrating that ctDNA dynamics can reflect treatment efficacy earlier than conventional imaging or PSA testing.
Sternberg et al. (2025) investigated whether ctDNA tumor fraction adds value to PSA in mCRPC and found that combining these biomarkers may improve risk stratification and response prediction.
Collectively, these studies indicate that ctDNA-guided treatment adaptation could refine clinical decision-making by identifying responders and non-responders earlier, potentially guiding therapy switches or intensifications.
Caveats and uncertainty
Despite encouraging data, several limitations constrain immediate clinical application. The sensitivity of ctDNA assays varies, and some patients exhibit low or undetectable ctDNA levels despite active disease, limiting universal applicability. Assay standardization, optimal sampling intervals, and thresholds for defining molecular response remain to be established.
Most evidence derives from relatively small cohorts or retrospective analyses, with a lack of large, prospective randomized trials validating ctDNA-guided treatment algorithms. The biological heterogeneity of mCRPC and variable ctDNA shedding complicate interpretation.
Furthermore, ctDNA results should be integrated with clinical, radiographic, and PSA data to avoid premature treatment changes based on isolated biomarker fluctuations.
How this may change practice
If validated in prospective clinical trials, ctDNA-guided treatment adaptation could become a valuable tool in managing mCRPC by enabling earlier identification of treatment response or resistance. This approach may facilitate more personalized therapy sequencing, reduce exposure to ineffective treatments, and improve patient outcomes.
Incorporating ctDNA monitoring alongside PSA and imaging could enhance risk stratification and support dynamic treatment decisions, especially in ambiguous clinical scenarios.
Currently, ctDNA analysis should be considered investigational and primarily used within research contexts or specialized centers with expertise in molecular oncology.